These are biotech's 44 most promising startups of the last half-decade — here's how they've ended up
When annually proclaiming which startups are poised to become the next big thing in biotech, you ought to track their progress every so often.
In the past five years, Endpoints News has profiled 44 private biotech startups exhibiting the hallmarks of great potential — scientific rigor, leadership gusto, deep pockets, ambition to take on what others haven’t or a fresh take on the industry.
So, in advance of announcing another batch of honorees this week, it’s time to reflect on the status of previous Endpoints 11 winners. (And sorry, Class of 2019, for neglecting to select any companies from your year.)
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.